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Research
AbstrAct
Objective To define important changes in management 
arising from the use of cardiovascular magnetic resonance 
(CMR) in patients who activate the primary percutaneous 
coronary intervention (PPCI) pathway.
Design Formal consensus study using literature review 
and cardiologist expert opinion to formulate consensus 
statements and setting up a consensus panel to review 
the statements (by completing a web-based survey, 
attending a face-to-face meeting to discuss survey 
results and modify the survey to reflect group discussion 
and completing the modified survey to determine which 
statements were in consensus).
Participants Formulation of consensus statements: 
four cardiologists (two CMR and two interventional) and 
six non-clinical researchers. Formal consensus: seven 
cardiologists (two CMR and three interventional, one 
echocardiography and one heart failure). Forty-nine 
additional cardiologists completed the modified survey.
Results Thirty-seven draft statements describing changes 
in management following CMR were generated; these 
were condensed into 12 statements and reviewed through 
the formal consensus process. Three of 12 statements 
were classified in consensus in the first survey; these 
related to the role of CMR in identifying the cause of out-
of-hospital cardiac arrest, providing a definitive diagnosis 
in patients found to have unobstructed arteries on 
angiography and identifying patients with left ventricular 
thrombus. Two additional statements were in consensus 
in the modified survey, relating to the ability of CMR to 
identify patients who have a poor prognosis after PPCI and 
assess ischaemia and viability in patients with multivessel 
disease.
Conclusion There was consensus that CMR leads to 
clinically important changes in management in five 
subgroups of patients who activate the PPCI pathway.
InTroducTIon
There has been rapid uptake of cardiovas-
cular magnetic resonance (CMR) in the UK, 
with a 44% increase in the number of scans 
per centre (from 557 to 802) between 2008 
and 2010.1 Despite the rapid increase in the 
number of scans undertaken, there is limited 
evidence about the impact of CMR on long-
term prognosis or treatment decisions. CMR 
is increasingly being used for patients who 
activate the primary percutaneous coronary 
intervention (PPCI) pathway, but it is not 
clear how CMR influences clinical manage-
ment in this population.
We conducted a study to determine the 
feasibility of setting up a prospective registry 
using routine data linkage to assess the clin-
ical and cost-effectiveness of CMR in patients 
who activate the PPCI pathway.2 A long-term 
objective of the registry is to compare the inci-
dence of major adverse cardiovascular events 
(MACE) in patients who do or do not have 
CMR after the index event. However, given 
the rare occurrence of such events in these 
patients, the study would have to accrue over 
Strengths and limitations of this study
 ► We used formal consensus methods to identify 
potentially important changes in management 
arising from the use of cardiac magnetic resonance 
(CMR) in patients who activate the primary 
percutaneous coronary intervention pathway.
 ► We identified five patient subgroups in this population 
in which CMR leads to clinically important changes 
in management.
 ► We did not include different stakeholder groups in 
the consensus panel as the technical wording of the 
statements would not have been easily understood 
by non-cardiologists.
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37 000 subjects to detect a clinically important reduction 
in the incidence of MACE with adequate power. There-
fore, a key objective of the feasibility study was to define 
a primary composite outcome, acceptable to cardiologists 
and other stakeholders (eg, clinical commissioners) as 
representing a clinically important change in manage-
ment as a result of an eligible patient having had CMR 
(eg, expected to prevent future MACE) that could be 
used for the registry in the medium term.
We used a formal consensus method based on 
the modified nominal group technique3 to identify 
important changes in management (and the specific 
patient subgroups these changes in management relate 
to) that can be used to define the composite outcome. 
Formal consensus is a method that combines both 
research evidence and expert opinion. We used this 
approach because we knew from a preliminary scoping 
of the literature that there were few studies that reported 
the impact of CMR on patient management. There were 
three components to the consensus process: (1) a litera-
ture review to identify evidence about the use of CMR in 
patients who activate the PPCI pathway, (2) formulation 
of statements about how CMR changes patient manage-
ment using research evidence and expert opinion and 
(3) the formal consensus involving an independent panel 
of cardiologists using surveys and discussion to reach 
consensus.
MeThods
Literature review and formulation of the consensus 
statements
An initial working group was convened including two 
cardiologists with CMR expertise, two interventional 
cardiologists from sites participating in the feasibility 
study, one cardiac network director, two methodologists, 
two statisticians, one health economist and the study 
manager. We conducted a literature review to search 
for studies reporting the impact of CMR on prognosis, 
patient management and risk stratification in the popu-
lation of patients who activate the PPCI pathway. We 
searched without restriction by study design or search 
terms related to outcomes, so that we could determine 
the full extent of the literature in this area and identify all 
studies that used CMR in our population. The search was 
conducted on Medline, Embase, The Cochrane Library, 
ISI Web of Science (Citations Index and Proceedings) 
and BIOSIS (see online supplementary appendix 1). The 
following search terms were used, both as free text and 
medical subject headings where possible: ‘acute coronary 
syndrome’, ‘myocardial infarction’, ‘angioplasty’, ‘percu-
taneous coronary intervention’, ‘cardiovascular magnetic 
resonance’. We applied no restriction on publication date 
or language.
Draft statements were generated independently by 
three of the cardiologists (based on clinical expertise) 
and by one methodologist (based on evidence from 
the systematic literature search). Three members of the 
working group (study manager, systematic reviewer and 
cardiologist with CMR expertise) collated the statements, 
organised them according to patient subgroup and stan-
dardised the wording of each statement. A supporting 
paragraph was drafted for each statement (citing key 
references from the literature review) to provide back-
ground information and put the statement in context. 
A 1-day meeting was organised for all members of the 
working group to consider the relevance, format and 
wording of each statement.
survey design
Statements and supporting paragraphs were worded 
in a consistent manner and collated in the form of a 
web-based survey (SurveyMonkey, Palo Alto, California, 
USA) (see online supplementary appendix 2). The survey 
included an introductory page explaining the purpose 
and layout of the survey and instructions about how to 
complete it. Each statement followed with its supporting 
paragraph containing links to PDF references. Each state-
ment was accompanied by a 9-point Likert scale asking 
the respondent to indicate whether he/she agreed with 
the statement or not (with 1 indicating ‘completely 
disagree’ and 9 ‘completely agree’). There was also a free 
text box for each statement for respondents to comment 
and justify their score.
establishing the expert panel
Clinicians in the working group identified consultant 
cardiologists with CMR, interventional, echocardiog-
raphy, electrophysiology and heart failure expertise from 
across the UK. The cardiologists were invited by email to 
form an expert consensus panel.
expert panel: completion of first survey
The expert panel completed the survey independently. 
Responses were collated and analysed by members of the 
working group.
expert panel: face-to-face meeting
The expert panel attended a face-to-face meeting, chaired 
by a non-cardiology clinician experienced in facilitating 
formal consensus panels. The meeting was also attended 
by non-clinical members of the working group, whose role 
was to introduce the study, describe the structure of the 
formal consensus process, provide study-related informa-
tion and take minutes of the meeting. The expert panel 
discussed each statement and anonymised responses to 
the first survey in turn and agreed on modifications to 
the survey.
expert panel: completion of the modified survey
The survey was modified by members of the working group 
as agreed in the face-to-face meeting (see online supple-
mentary appendix 3). The expert panel completed the 
modified survey independently and rated the statements 
a second time.
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extension of survey to other uK cardiologists
The survey was extended to other UK cardiologists 
through the British Cardiovascular Society, which adver-
tised the survey in their monthly newsletter to members 
(over 2 consecutive months).
criteria for consensus
Data for each statement are shown as median and IQR. 
A median score of ≥7 and IQR of 6–9 were considered 
to be in agreement or consensus that the change in 
management described by the statement was clinically 
important. These statements were used to identify the 
patient subgroups perceived to benefit from CMR and 
define the treatment/process outcome that constitutes a 
definitive management change as a result of having CMR. 
A median score of ≤3 and IQR of 1–3 were considered to 
be in consensus that the statement did not constitute a 
clinically important change in management. Data were 
analysed using Stata/IC (Version 14).
resuLTs
Literature review and formulation of consensus statements
Thirty-seven draft statements were generated by the 
three cardiologists and one methodologist. The litera-
ture search identified a total of 171 studies reporting the 
use of CMR in patients with acute myocardial infarction 
(MI) who activated the PPCI pathway. There were no 
studies that directly compared groups of patients having 
CMR or not with respect to patient management or clin-
ical outcomes in this population. Statements relating 
to the same patient subgroup/condition (eg, patients 
at risk for complications after PPCI who develop left 
ventricular (LV) thrombus) were condensed into one 
statement. Participants at the working group combined 
some statements to avoid repetition and clarified the 
care pathway without CMR compared with which the 
additional benefit of CMR was anticipated, for example, 
alternative imaging modalities such as echocardiography 
or single-photon emission CT(SPECT). This process 
resulted in 12 statements (see online supplementary 
appendix 3) describing changes in management relating 
to six patient subgroups:
1. patients with poor prognosis or at risk for complications 
after PPCI (five statements);
2. patients with good prognosis after PPCI who could 
be discharged earlier and followed up less often (one 
statement);
3. patients with multivessel disease (MVD) (two 
statements);
4. patients with unobstructed arteries on angiography 
(one statement);
5. patients with out-of-hospital cardiac arrest (OHCA) 
(one statement); and
6. patients with incidental cardiac and extracardiac 
findings (two statements).
The expert panel
Nineteen consultant cardiologists were invited to partic-
ipate in the consensus process. Seven cardiologists (37% 
of those invited) agreed to participate. Of these, two 
had CMR, three had interventional, one had echocardi-
ography and one had heart failure expertise. All seven 
cardiologists completed the first survey independently.
First survey
There was consensus for 3 of the 12 statements (25%) 
that the change in management was clinically important 
(see online supplementary appendix 4): the ability of 
CMR to identify the cause of OHCA and therefore opti-
mise treatment for the patient; the ability of CMR to 
provide a definitive diagnosis in patients found to have 
unobstructed arteries on angiography; and the ability of 
CMR to identify patients with LV thrombus and initiate 
treatment with anticoagulation therapy. There was no 
consensus for any statement that the change in manage-
ment described was not clinically important.
Consensus was sought on the importance of the change 
in management, and most respondents commented 
on this issue. However, some respondents also consid-
ered other factors when rating statements, for example, 
the quality of the supporting evidence, the proportion 
of patients likely to benefit, the ability of the National 
Health Service (NHS) to provide a service in line with 
the statement and whether the cost of CMR justified the 
perceived benefit.
Face-to-face meeting
The face-to-face meeting was attended by six of the seven 
cardiologists and three non-clinical members of the initial 
working group. As a result of the face-to-face meeting, the 
survey was modified as follows:
1. The number of statements was reduced from 12 to 10. 
One statement (relating to patients with MVD) was 
removed because cardiologists felt that it overlapped 
significantly with a second statement relating to 
patients with MVD. Statements relating to incidental 
cardiac and extracardiac findings were combined into 
one statement.
2. Respondents were asked to rate five aspects of each 
statement, organised hierarchically: (a) whether CMR 
is better than the comparator (eg, echocardiography); 
(b) whether the information from CMR leads to a 
change in management; (c) whether the change 
in management is clinically important (ie, likely to 
reduce risk of MACE in the long term); (d) whether 
the change in management is likely to reduce NHS 
costs in the long term; (e) whether the anticipated 
benefit was sufficiently large to make CMR cost-
effective among the patients in whom it would be 
indicated (see online supplementary appendix 3). 
Consensus was based on the distribution of responses 
to questions (a) to (c) of each statement (ie, 
median ≥7, IQR 6–9 for clinically important changes 
in management and median ≤3 and IQR 1–3 for 
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(a), (b) and (c)). Responses to questions (a) to (c) 
were used because (a) was constructed to interrogate 
the respondent’s appraisal of the evidence, (b) was 
constructed to determine whether the respondent 
believed the NHS delivery changed as a result of 
CMR and (c) was constructed to determine whether 
the respondent believed that any change recognised 
in (b) was clinically important. Discussions in the 
meeting revealed that consideration of costs and 
cost-effectiveness for the NHS influenced some panel 
member’s responses to the initial survey. Questions 
(d) and (e) were added to isolate these aspects of 
consideration and separate them from the question 
of change in management, which was the aim of the 
consensus process.
3. The free text box in which respondents could justify 
their score was removed. The modified survey is 
shown in table 1.
Modified survey
Fifty-four cardiologists (including five of the cardiol-
ogists who attended the formal consensus meeting) 
completed the survey. There was consensus that 5 of 
the 10 statements (50%) described clinically important 
changes in management (figure 1). These were state-
ments 3, 5 and 9 (which were in consensus in the first 
survey) and two additional statements: statement 1, 
relating to the ability of CMR to identify patients who 
have a poor prognosis after PPCI, and statement 8, 
relating to the ability of CMR to assess ischaemia and 
viability in patients with MVD. There was no consensus 
that any of the other statements described a change in 
management that was not clinically important. Exam-
ples of comments relating to these five statements 
from cardiologists who attended the formal consensus 
meeting are shown in table 2.
dIscussIon
We identified five subgroups of acute coronary syndrome 
(ACS) patients who activate the PPCI pathway for whom 
there was consensus that CMR changes patient manage-
ment in a clinically important way: (i) patients who have 
an OHCA (about 7% of those who activate the PPCI 
pathway4); (ii) patients who have a ‘normal’ (unob-
structed) coronary angiogram (about 10% of those who 
activate the PPCI pathway5 6); (iii) patients who develop 
LV thrombus (3% overall and 9% in patients with anterior 
ST-elevation MI (STEMI)7; (iv) patients who have MVD 
(between 40% and 65% of those who undergo PPCI)8–10; 
and (v) patients in whom CMR markers indicate poor 
prognosis (up to 60% of patients after STEMI).11 12 There 
was consensus about the first three subgroups in both 
rounds of the survey, while consensus was reached about 
the latter subgroups in the modified survey. These results 
suggest that CMR benefits a large proportion of patients 
who activate the PPCI pathway.
evidence for the roles for cMr in patients who activate the 
PPcI pathway
Cardiologists who participated in our research agreed 
that CMR is superior to echocardiography in establishing 
a diagnosis in patients who survive an OHCA, which has 
implications for treatment and prognosis. Despite this 
view, there are few studies that have reported the role of 
CMR in managing these patients. An unpublished retro-
spective case series of 54 OHCA survivors showed that 
CMR diagnosed the cause (ischaemic or non-ischaemic 
cardiomyopathy) in 40 (74%).13
The cardiologists also agreed that CMR can provide 
a definitive diagnosis (acute MI, acute myocarditis and 
cardiomyopathy, especially Takotsubo cardiomyop-
athy) in patients with ACS and unobstructed coronary 
arteries. Evidence for the role of CMR in patients with 
ACS and unobstructed coronary arteries also comes from 
small retrospective case series. These suggest that CMR 
provides a definitive diagnosis in 80%–90% of these 
patients.14–16 Without access to CMR, the management of 
these patients is variable in clinical practice, which may 
have long-term implications. A recent systematic review 
showed that the overall all-cause mortality in patients 
presenting with suspected MI and unobstructed coronary 
arteries was about 5% at 12 months.17
The cardiologists agreed that CMR identifies LV 
thrombus better than echocardiography, which allows 
more patients to be identified and treated appropriately. 
Accurate identification of an LV thrombus is important 
because it often directs subsequent anticoagulation 
therapy to prevent embolic events. A recent system-
atic review, published after we conducted the formal 
consensus study, showed that late gadolinium enhance-
ment CMR is the most accurate modality for detecting 
LV thrombus, with 88% sensitivity and 99% specificity 
(compared with routine echocardiography, which had 
24%–33% sensitivity and 94%–95% specificity, and 
contrast echocardiography, which had 23%–61% sensi-
tivity and 96%–99% specificity),18 although most of the 
included studies in this review did not use a patholog-
ical or surgical gold standard for the detection of LV 
thrombus.
There was agreement among cardiologists that a 
CMR-based testing of ischaemia after PPCI would likely 
optimise the revascularisation strategy for these patients, 
although they acknowledged that there is no evidence 
to support the view that a CMR-based revascularisation 
strategy would improve outcomes for patients with MVD 
(see table 2). Patients with MVD have a twofold increase 
in MACE compared with patients with single-vessel 
disease.19 There is continuing debate about the benefits 
of complete versus single-lesion revascularisation during 
the index PPCI admission.20 Despite recent evidence 
from randomised controlled trials showing improved 
clinical outcomes when complete revascularisation is 
undertaken at PPCI,21 current American and European 
revascularisation guidelines for acute MI recommend 
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Table 1 Consensus statements (modified survey)
Statement
1 The following statements relate to the ability of CMR to identify patients who have a poor prognosis after PPCI:
a. CMR markers (eg, impaired LV function, large infarct size, microvascular obstruction) better identify patients with a 
poor prognosis after PPCI than markers based on echocardiography.
b. Better identification of patients with a poor prognosis after PPCI allows these patients to be followed up more 
appropriately and treated more aggressively.
c. More appropriate follow-up and more aggressive treatment in these patients are expected to lead to a reduced risk 
of MACE in the long term.
2 The following statements relate to the ability of CMR to identify patients who have a good prognosis after PPCI:
a. CMR markers (eg, normal LV function, high myocardial salvage, no microvascular obstruction, no residual ischaemia) 
better identify patients with a good prognosis after PPCI than markers based on echocardiography.
b. Better identification of patients with a good prognosis after PPCI allows these patients to be followed up less 
frequently.
c. Less-frequent follow-up in these patients is expected to lead to less NHS resource use in the long term.
3 The following statements relate to the ability of CMR to identify the causes of OHCA in patients who undergo an 
emergency angiogram:
a. CMR better identifies the cause of OHCA (eg, large myocardial infarction, ARVC, aberrant coronary arteries, HCM) 
than echocardiography.
b. Better identification of the cause of OHCA allows treatment to be optimised for these patients (eg, defibrillator 
for primary arrhythmia or percutaneous coronary intervention) or their family members (eg, genetic screening and 
counselling, primary prevention).
c. The ability to optimise treatment for these patients or family members is expected to lead to a reduced risk of 
MACE in the long term.
4 The following statements relate to the ability of CMR to identify patients with VSD after myocardial infarction:
a. CMR identifies the location and characteristics of postinfarct VSD better than echocardiography.
b. Better identification of the location and characteristics of postinfarct VSD guides the optimal management of these 
patients.
c. Optimal management of patients with postinfarct VSD is expected to lead to a reduced risk of MACE in the long 
term.
5 The following statements relate to the ability of CMR to differentiate myocardial infarction from other diagnoses in 
patients found to have unobstructed coronary arteries on emergency angiography:
a. Unlike echocardiography, CMR can provide a definitive ischaemic diagnosis (eg, myocardial infarction with 
spontaneous reperfusion or distal embolization) or a non-ischaemic diagnosis (eg, myocarditis, Takotsubo 
cardiomyopathy, aortic dissection) in patients with unobstructed coronary arteries on angiography.
b. A definitive diagnosis results in a patient treatment plan appropriate for that diagnosis.
c. A treatment plan appropriate for the diagnosis is expected to lead to a reduced risk of MACE in the long term.
6 The following statements relate to the ability of CMR to identify patients at high risk for sudden cardiac death after PPCI 
who would benefit most from an implantable cardiac device:
a. CMR identifies PPCI patients who are at high risk for sudden cardiac death better than echocardiography.
b. Better identification of PPCI patients at high risk for sudden cardiac death allows optimal patient selection for an 
implantable cardiac device (ICD or CRT).
c. Optimal patient selection for an implantable cardiac device is expected to lead to a reduced risk of MACE in these 
patients in the long term.
7 The following statements relate to the ability of CMR to identify patients who would not benefit from CRT after PPCI:
a. CMR identifies patients who would not benefit from CRT better than echocardiography.
b. The ability to identify patients who would not benefit from CRT would reduce CRT use in patients who do not need 
it.
c. Reducing CRT use in patients who do not need it is expected to lead to reduced risk of MACE in these patients in 
the long term.
8 The following statements relate to the ability of CMR to assess ischaemia and viability in patients with multivessel 
disease:
a. CMR assesses ischaemia and viability of the myocardium better than echocardiography.
b. Better assessment of ischaemia and viability of the myocardium optimises the revascularisation strategy for 
patients with multivessel disease and avoids additional diagnostic tests.
c. The ability to optimise the revascularisation strategy for patients with multivessel disease is expected to lead to a 
reduced risk of MACE in the long term.
Continued
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revascularisation only of the infarct-related artery at PPCI 
in patients with MVD.22 23
There was considerable debate about using CMR to 
identify patients with poor prognosis after PPCI. While 
there was agreement that CMR parameters of cardiac 
function (eg, impaired LV function, large infarct size, 
microvascular obstruction, etc) are useful for risk stratifi-
cation after STEMI, there was disagreement about whether 
this would lead to a management change. Some cardiol-
ogists felt that there would be no changes to prescribing 
for secondary prevention since all patients should receive 
aggressive secondary prevention according to guidelines 
(see table 2). It was acknowledged, however, that CMR 
markers are prognostic for outcome (statement 1a in 
table 1); two recent meta analyses of prognostic studies 
(conducted after this formal consensus study) showed 
an increased risk of MACE, by 13%–15% for every 10% 
decrease in ejection fraction assessed by CMR,11 and in 
patients with microvascular obstruction (MVO) assessed 
by CMR (OR 2.60, 95% CI 1.68 to 4.02, and OR 4.30, 
95% CI 2.19 to 8.43, depending on method of MVO 
assessment).24
strengths and limitations
A key strength of this study was the use of a formal 
consensus approach, based on a systematic search of the 
literature as well as expert opinion. The nominal group 
technique is one of the four well-established methodolo-
gies for formal consensus (the other three are the Delphi 
method, RAND/UCLA Appropriateness Method and 
National Institutes of Health consensus development 
conference methodology).2 25 Formal consensus is partic-
ularly useful to clarify and standardise practice when 
relevant and rigorous evidence is lacking. The evidence 
supporting many of our statements came from small retro-
spective case series. There were no prospective studies in 
the literature that reported the impact of CMR on clinical 
management in our population or whether any changes 
in management impacted on patient outcomes.
The main features of a formal consensus method are 
anonymity (statements were rated free from peer-group 
pressure) and iterative feedback (participants could 
adjust their initial rating based on the feedback of the 
group rating). We described the supporting evidence for 
each statement, identified via the literature review and 
fed back qualitative (panel members’ comments) and 
quantitative (group median ratings of each statement) 
information at the face-to-face meeting. We also included 
a varied group of cardiologists from different specialties 
in order to encompass diverse perspectives.
The number of panel members in our study was lower 
than the recommended 8–12 members for a consensus 
panel.25 Nevertheless, smaller groups are preferable to 
Statement
9 The following statements relate to the ability of CMR to identify patients with postinfarct LV thrombus:
a. CMR identifies postinfarct LV thrombus better than transthoracic echocardiography.
b. Better detection of postinfarct LV thrombus in PPCI patients allows more affected patients to be treated with 
anticoagulation therapy.
c. Treatment with anticoagulation therapy in patients with postinfarct LV thrombus is expected to lead to a reduced 
risk of MACE in the long term.
10 The following statements relate to the ability of CMR to detect incidental cardiac and non-cardiac findings if offered 
routinely to patients who undergo an emergency angiogram:
a. CMR identifies more incidental cardiac/non-cardiac findings than echocardiography.
b. Improved detection of potentially significant incidental findings allows affected patients to be investigated further 
and/or treated.
c. Further investigation and treatment are expected to reduce the risk of MACE/increase overall survival in affected 
patients in the long term.
ARVC, arrhythmogenic right ventricular cardiomyopathy; CMR, cardiovascular magnetic resonance; CRT, cardiac resynchronization therapy; 
HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; LV, left ventricular; MACE, major adverse cardiovascular 
events; NHS, National Health Service; OHCA, out-of-hospital cardiac arrest; PPCI, primary percutaneous coronary intervention; VSD, 
ventricular septal defect.
Table 1 Continued 
Figure 1 Median and IQR for the 10 statements in the 
modified survey (n=54). Boxes represent the median and 
IQR, and the whiskers represent the range. Dots represent 
extreme values. Consensus was based on the distribution 
of responses to a, b and c. Statements 1, 3, 5, 8 and 9 were 
considered to be in consensus.
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larger ones since, although having more group members 
increases the reliability of group judgement, large groups 
reduce the ability to elicit potentially important contri-
butions from every member of the panel.25 To overcome 
any criticism of the number of panel members in our 
study and to prevent the possibility of introducing bias 
(given the self-selected nature of the panel), we extended 
the survey to UK cardiologists who did not participate in 
the formal consensus process. Apart from one statement 
(statement 1, relating to the ability of CMR to identify 
patients with poor prognosis after PPCI), the same state-
ments were in consensus when the survey was completed 
by cardiologists external to the consensus process. This 
indicates that our process was robust and our survey state-
ments were clear and unambiguous.
A further limitation of our study was that we did not 
include other stakeholders (eg, general practitioners 
and patient representatives) in the consensus process.26 
Although we had originally planned to do so, we decided 
that the specialised nature of the statements would not be 
easily understood by those without cardiology expertise.
conclusion and future research
We have identified the main ways in which cardiolo-
gists believe CMR changes clinical management in five 
subgroups of patients who activate the PPCI pathway. 
These clinically important changes in management can 
now be used to design a composite primary outcome for 
an evaluation of the effectiveness and cost-effectiveness 
of CMR. This will allow evidence to be obtained more 
quickly to inform decisions about implementing CMR 
than would be possible for an evaluation based on MACE.
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